Based on the assumption that Gal-3 is responsible for a promoting effect on IPF and considering the lack of effective treatment for this pulmonary condition, it has been postulated that Gal-3 may represent a possible new target for treatment. The gene discussed is LGALS3; the disease is idiopathic pulmonary fibrosis.